BIBW 2992 (Afatinib) in Head & Neck Cancer

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Boehringer Ingelheim
ClinicalTrials.gov Identifier:
NCT00514943
First received: August 9, 2007
Last updated: July 21, 2014
Last verified: July 2014

August 9, 2007
July 21, 2014
August 2007
March 2010   (final data collection date for primary outcome measure)
Tumor Shrinkage Before Crossover Per Investigator Assessment [ Time Frame: From randomization until start of Stage 2 treatment, or within 28 days after the termination of Stage 1. ] [ Designated as safety issue: No ]
Tumor shrinkage before crossover was defined as the change from baseline in the smallest post-randomisation sum of the longest diameters of target lesions (SLD), calculated as the smallest SLD after randomisation but before crossover minus SLD at baseline. Baseline was the SLD measured before randomisation. A negative value means the smallest post-randomisation SLD was smaller than baseline (decreased since baseline); a positive value means tumor size increased since baseline.
Tumor shrinkage before cross over to Stage 2 of the trial.
Complete list of historical versions of study NCT00514943 on ClinicalTrials.gov Archive Site
  • Tumor Shrinkage After Crossover (Stage 2) Per Investigator Assessments [ Time Frame: From baseline assessed prior to first dose of Stage 2 study medication to 28 days after termination of Stage 2 treatment. ] [ Designated as safety issue: No ]
    Tumor shrinkage after crossover was defined as the change from baseline in the smallest post-crossover sum of the longest diameters of target lesions (SLD), calculated as the smallest SLD after crossover minus SLD at baseline. Baseline was the SLD measured at the time of crossover, or the closest measurement before the patient started stage 2 treatment. A negative value means the smallest post-crossover SLD was smaller than baseline (decreased after crossover), a positive value means tumor size increased after crossover.
  • Best Overall Response Per Investigator Assessment for Stage 1 [ Time Frame: Response determined from randomization until patient started Stage 2 or within 28 days after termination of Stage 1 treatment ] [ Designated as safety issue: No ]
    Overall response is assessed by the investigator according to the RECIST 1.0.
  • Best Overall Response Per ICR for Stage 1 [ Time Frame: Response determined from randomization until patient started Stage 2 or within 28 days after termination of Stage 1 treatment ] [ Designated as safety issue: No ]
    Overall response is assessed by independent central review (ICR) according to the RECIST 1.0.
  • Best Overall Response Per Investigator Assessment for Stage 2 [ Time Frame: Response determined during Stage 2 or within 28 days after termination of Stage 2 treatment ] [ Designated as safety issue: No ]
    Overall response is assessed by the investigator according to the RECIST 1.0.
  • Best Overall Response Per ICR for Stage 2 [ Time Frame: Response determined during Stage 2 or within 28 days after termination of Stage 2 treatment ] [ Designated as safety issue: No ]
    Overall response is assessed by independent central review (ICR) according to the RECIST 1.0.
  • Overall Survival (OS) Time [ Time Frame: From randomisation to data cut-off date. ] [ Designated as safety issue: No ]
    OS is defined as time from randomisation to death.
  • Progression Free Survival (PFS) Before Crossover Based on Investigator Assessment [ Time Frame: From randomisation to disease progression in Stage 1 or death whichever came first before crossover. ] [ Designated as safety issue: No ]
    PFS is defined as time from randomisation to until the occurrence of tumor progression or death, whichever came first, during Stage 1 of the trial.
  • Progression Free Survival (PFS) After Crossover Based on Investigator Assessment [ Time Frame: From first administration of study medication after cross over to disease progression in Stage 2 or death whichever came first after crossover. ] [ Designated as safety issue: No ]
    PFS is defined as time from first administration study medication after cross over until the occurrence of tumor progression or death, whichever came first, during Stage 2 of the trial.
  • Time to Deterioration in HRQoL - Stage 1 [ Time Frame: From randomisation to deterioration in HRQoL scores before crossover. ] [ Designated as safety issue: No ]

    Health related Quality of Life (HRQoL) was assessed with the questionnaires EORTC QLQ-C30 and EORTC QLQ-H&N35.

    Time to deterioration in HRQoL (defined as a 10-point change towards worsening from the baseline score on a 0-100 point scale) was determined for:

    • global health status (QLQ−C30 items 29 and 30)
    • pain (QLQ−HN35 items 31 to 34)
    • swallowing (QLQ−HN35 items 35 to 38)
  • Pre-dose Concentration of Afatinib in Plasma at Steady State on Day 15 (Cpre,ss,15) [ Time Frame: Day 15 ] [ Designated as safety issue: No ]
    Cpre,ss,15 represents the pre-dose concentration of afatinib in plasma at steady state on day 15.
  • Patients With AEs Resulting in Diarrhea and Skin Rash [ Time Frame: First administration of trial medication until 28 days after last ] [ Designated as safety issue: Yes ]
    Patients with adverse events (AEs) resulting in Diarrhea and skin rash.
Tumor shrinkage after crossover Best RECIST assessment PFS OS Quality of Life Adverse Events
Not Provided
Not Provided
 
BIBW 2992 (Afatinib) in Head & Neck Cancer
A Randomized, Open-label Phase II Study of BIBW 2992 Versus Cetuximab (Erbitux) in Patients With Metastatic or Recurrent Head and Neck Squamous Cell Carcinoma (HNSCC) After Failure of Platinum-containing Therapy With a Cross-over Period for Progressing Patients

The primary objective of this study is to explore the efficacy of BIBW 2992 compared with cetuximab (Erbitux) in patients with metastatic or recurrent head and neck cancer after failure of platinum-containing therapy. In addition, the trial aims to clarify the influence of EGFR genotype on tumor response to the treatment regimens.

Not Provided
Interventional
Phase 2
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Crossover Assignment
Masking: Open Label
Primary Purpose: Treatment
  • Head and Neck Neoplasms
  • Carcinoma, Squamous Cell
  • Drug: BIBW 2992
    experimental drug taken once daily orally
  • Drug: Cetuximab
    active comparator administered weekly intravenously
  • Experimental: BIBW 2992
    once daily taken orally
    Intervention: Drug: BIBW 2992
  • Active Comparator: Cetuximab
    once every week by intravenous injection
    Intervention: Drug: Cetuximab
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
124
July 2013
March 2010   (final data collection date for primary outcome measure)

Inclusion criteria:

1. Metastatic (stage IVc) or recurrent HNSCC 2. Histologically or cytologically confirmed diagnosis of squamous cell of the head and neck. Patients with well-differentiated (keratinizing) nasopharyngeal carcinomas and patients with squamous cell carcinomas metastatic to the neck from an unknown head and neck primary are eligible. 3. Patients must have documented progressive disease (PD) following receipt of prior platinum-based therapy (either as neoadjuvant, adjuvant, concomitant with radiotherapy, or for recurrent/ metastatic disease). 4. Patients must have measurable disease as defined by RECIST criteria. 5. Patients must have recovered from any therapy-related toxicities from previous chemo-, immuno-, or radiotherapies to CTC smaller or equal to Grade 1. 6. Patients must have recovered from previous surgery. 7. Life expectancy of at least three (3) months. 8. Eastern Cooperative Oncology Group (ECOG, R01-0787) performance score 0 or 1.

9. Patients must be eighteen (18) years of age or older. 10. Willingness and ability to give written informed consent consistent with ICH-GCP guidelines.

Exclusion criteria:

  1. Progressive disease within 3 months after completion of curative intent treatment for localized/locoregionally advanced disease.
  2. Prior use of an EGFR or erbB2 inhibitor in the recurrent/metastatic disease setting (treatment with cetuximab (Erbitux®) or other EGFR inhibitor during radiotherapy or chemoradiotherapy is permissible).
  3. More than 2 chemotherapeutic regimens given for recurrent/metastatic disease.
  4. Treatment with other investigational drugs, other anti-cancer-therapy (e.g., chemotherapy, immunotherapy, radiotherapy), concomitantly with therapy on this study and/or during the last four weeks, prior to the first treatment with the trial drug
  5. eliminated per Amendment #1
  6. Patients with history of other malignancy (except for appropriately treated superficial basal cell skin cancer and surgically cured cervical cancer in situ) unless free of disease for at least 3 years.
  7. Patients with history of decompensated heart failure.
  8. Cardiac left ventricular function with resting ejection fraction <50% or less than the institutional lower limit of normal by MUGA or echocardiogram.
  9. Active infectious disease.
  10. Gastrointestinal disorders that may interfere with the absorption of the study drug or chronic diarrhea.
  11. Serious illness, concomitant non-oncological disease or mental problems considered by the investigator to be incompatible with the protocol.
  12. Use of alcohol or drugs incompatible with patient participation in the study in the investigator's opinion.
  13. Patients unable to comply with the protocol.
  14. Patients with active/symptomatic brain metastases. Patients with a history of treated brain metastases must have stable or normal cerebral MRI scan at screening and be at least three months post-radiation or surgery.
  15. Absolute neutrophile count (ANC) less than 1000/mm3.
  16. Platelet count less than 75,000/mm3.
  17. Bilirubin greater than 1.5 mg/dl/ Higher bilirubin values are acceptable for patients with known Gilbert's disease, approval by the PI and sponsor necessary.
  18. Asparate amino transferase (AST) or alanine amino transferase (ALT) greater than 3 times the upper limit of normal.
  19. Serum creatinine greater than 1.5 X upper limit of normal for the institution.
  20. Patients who are sexually active and unwilling to use a medically acceptable method of contraception.
  21. Pregnancy or breast-feeding.
  22. Patients with known pre-existing interstitial lung disease.
Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
United States,   Belgium,   France,   Spain
 
NCT00514943
1200.28, 2008-007097-38
Not Provided
Boehringer Ingelheim
Boehringer Ingelheim
Not Provided
Study Chair: Boehringer Ingelheim Boehringer Ingelheim
Boehringer Ingelheim
July 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP